Gene therapy company Lexeo Therapeutics nabs $100m Series B

Lexeo Therapeutics, a clinical-stage gene therapy company, has secured $100 million in Series B financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this